We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Characterization of the trigeminovascular actions of several adenosine A<sub>2A</sub> receptor antagonists in an in vivo rat model of migraine.
- Authors
Haanes, Kristian A.; Labastida-Ramírez, Alejandro; Chan, Kayi Y.; de Vries, René; Danser, Alexander H. J.; MaassenVanDenBrink, Antoinette; Shook, Brian; Jackson, Paul; Zhang, Jimmy; Flores, Christopher M.; Villalón, Carlos M.
- Abstract
Background: Migraine is considered a neurovascular disorder, but its pathophysiological mechanisms are not yet fully understood. Adenosine has been shown to increase in plasma during migraine attacks and to induce vasodilation in several blood vessels; however, it remains unknown whether adenosine can interact with the trigeminovascular system. Moreover, caffeine, a non-selective adenosine receptor antagonist, is included in many over the counter anti-headache/migraine treatments.Methods: This study used the rat closed cranial window method to investigate in vivo the effects of the adenosine A2A receptor antagonists with varying selectivity over A1 receptors; JNJ-39928122, JNJ-40529749, JNJ-41942914, JNJ-40064440 or JNJ-41501798 (0.3-10 mg/kg) on the vasodilation of the middle meningeal artery produced by either CGS21680 (an adenosine A2A receptor agonist) or endogenous CGRP (released by periarterial electrical stimulation).Results: Regarding the dural meningeal vasodilation produced neurogenically or pharmacologically, all JNJ antagonists: (i) did not affect neurogenic vasodilation but (ii) blocked the vasodilation produced by CGS21680, with a blocking potency directly related to their additional affinity for the adenosine A1 receptor.Conclusions: These results suggest that vascular adenosine A2A (and, to a certain extent, also A1) receptors mediate the CGS21680-induced meningeal vasodilation. These receptors do not appear to modulate prejunctionally the sensory release of CGRP. Prevention of meningeal arterial dilation might be predictive for anti-migraine drugs, and since none of these JNJ antagonists modified per se blood pressure, selective A2A receptor antagonism may offer a novel approach to antimigraine therapy which remains to be investigated in clinical trials.
- Subjects
ADENOSINES; ANIMAL experimentation; BLOOD plasma; VASODILATION; CELL receptors; MENINGEAL artery; MIGRAINE; MOLECULAR structure; RATS; IN vivo studies; CHEMICAL inhibitors
- Publication
Journal of Headache & Pain, 2018, Vol 19, Issue 1, p1
- ISSN
1129-2369
- Publication type
Article
- DOI
10.1186/s10194-018-0867-x